Drug Profile
S 488210
Alternative Names: RSC-488210; S-488210Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator OncoTherapy Science
- Developer Shionogi
- Class Cancer vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Squamous cell cancer
Most Recent Events
- 01 Dec 2022 S 488210 is still in phase II trials for squamous cell carcinoma in Germany (OncoTherapy Science pipeline, September 2022)
- 01 Dec 2022 S 488210 is still in phase II trials for squamous cell carcinoma in Belgium (OncoTherapy Science pipeline, September 2022)
- 06 Jan 2020 Phase-II development is ongoing Germany and Belgium (Shionogi pipeline, January 2019)